Good clinical practices in the bioanalytical laboratory

Author:

Tudan Christopher1

Affiliation:

1. Veloxity Labs, 801 W Main St, Peoria, IL 61606, USA

Abstract

Despite the existence of good clinical practice guidelines, the way in which they are applied to the bioanalytical laboratory remains unclear. Aspects of patient confidentiality, informed consent and subject withdrawal; addressing unblinding associated with sample analysis, including repeat analysis and incurred sample reanalysis; or the differences in responsibilities between the sponsor and contract research organization are not articulated by the US FDA within the bioanalytical setting, and for most bioanalytical laboratories this remains a gap in their standard operating procedures. The aim of this article is to identify and clarify the aspects of the good clinical practices that are applicable to the bioanalytical laboratory when conducting bioanalysis with clinical samples, and to address potential gaps in the bioanalytical laboratory when it comes to clinical sample bioanalysis.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Reference21 articles.

1. European Medicines Agency. EMA Guideline on bioanalytical method validation (EMEA/CHMP/EWP/192217/2009) (2012). www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf

2. International Conference on Harmonisation. ICH Harmonized Guideline – bioanalytical method validation and study sample analysis M10 (2022). https://database.ich.org/sites/default/files/M10_Guideline_Step4_2022_0524.pdf

3. International Conference on Harmonisation. ICH E6(R2) Integrated Addendum to ICH E6(R1): guideline for good clinical practice E6(R2) (2016). https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf

4. US Food and Drug Administration. US FDA 21 CFR Part 312 – investigational new drug application. www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312

5. US Food and Drug Administration. US FDA 21 CFR Part 320 – bioavailability and bioequivalence requirements. www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-320

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3